Viatris ROE 2010-2024 | VTRS

Current and historical return on equity (ROE) values for Viatris (VTRS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Viatris ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-09-30 $-0.88B $19.79B -4.43%
2024-06-30 $-0.65B $19.52B -3.20%
2024-03-31 $-0.06B $20.01B -0.27%
2023-12-31 $0.05B $20.47B 0.26%
2023-09-30 $1.83B $20.87B 8.75%
2023-06-30 $1.85B $20.84B 9.04%
2023-03-31 $1.90B $20.93B 9.40%
2022-12-31 $2.08B $21.07B 10.32%
2022-09-30 $0.80B $19.18B 4.02%
2022-06-30 $0.76B $19.81B 3.72%
2022-03-31 $0.17B $20.45B 0.81%
2021-12-31 $-1.27B $20.49B -6.02%
2021-09-30 $-1.92B $21.14B -8.86%
2021-06-30 $-2.05B $21.21B -10.48%
2021-03-31 $-1.73B $21.42B -10.07%
2020-12-31 $-0.67B $22.95B -4.58%
2020-09-30 $0.27B $12.55B 2.25%
2020-06-30 $0.27B $11.75B 2.34%
2020-03-31 $0.06B $11.26B 0.54%
2019-12-31 $0.02B $11.88B 0.14%
2019-09-30 $0.05B $11.46B 0.40%
2019-06-30 $0.03B $11.90B 0.28%
2019-03-31 $0.24B $11.89B 1.99%
2018-12-31 $0.35B $12.17B 2.85%
2018-09-30 $0.55B $12.07B 4.30%
2018-06-30 $0.46B $12.21B 3.52%
2018-03-31 $0.72B $13.18B 5.44%
2017-12-31 $0.70B $13.31B 5.44%
2017-09-30 $0.87B $13.29B 7.11%
2017-06-30 $0.66B $12.83B 5.57%
2017-03-31 $0.53B $11.66B 4.74%
2016-12-31 $0.48B $11.12B 4.41%
2016-09-30 $0.26B $11.83B 2.44%
2016-06-30 $0.81B $10.33B 8.02%
2016-03-31 $0.81B $10.28B 8.18%
2015-12-31 $0.85B $9.77B 8.88%
2015-09-30 $0.84B $9.82B 10.62%
2015-06-30 $0.91B $9.57B 14.41%
2015-03-31 $0.87B $9.09B 18.19%
2014-12-31 $0.93B $3.28B 28.09%
2014-09-30 $0.92B $3.41B 28.50%
2014-06-30 $0.58B $3.35B 18.21%
2014-03-31 $0.63B $3.19B 20.54%
2013-12-31 $0.62B $2.96B 20.76%
2013-09-30 $0.61B $3.23B 19.52%
2013-06-30 $0.66B $2.95B 20.54%
2013-03-31 $0.62B $2.89B 18.95%
2012-12-31 $0.64B $3.36B 18.37%
2012-09-30 $0.61B $3.62B 17.24%
2012-06-30 $0.55B $3.20B 15.85%
2012-03-31 $0.56B $3.78B 15.31%
2011-12-31 $0.54B $3.51B 14.49%
2011-09-30 $0.41B $3.49B 11.00%
2011-06-30 $0.36B $3.88B 9.65%
2011-03-31 $0.27B $3.92B 7.57%
2010-12-31 $0.22B $3.62B 6.70%
2010-09-30 $0.22B $3.54B 6.98%
2010-06-30 $0.08B $2.98B 2.46%
2010-03-31 $0.08B $3.18B 2.70%
2009-12-31 $0.09B $3.15B 3.16%
Sector Industry Market Cap Revenue
Medical Medical Services $15.576B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $91.424B 11.34
Cencora (COR) United States $47.484B 17.51
DiDi Global (DIDIY) China $23.330B 0.00
Natera (NTRA) United States $21.401B 0.00
ICON (ICLR) Ireland $16.136B 14.37
Avantor (AVTR) United States $13.422B 20.12
Revvity (RVTY) United States $13.376B 23.24
CochLear (CHEOY) Australia $12.844B 0.00
BioMerieux (BMXMF) France $12.666B 0.00
Solventum (SOLV) United States $11.583B 0.00
Medpace Holdings (MEDP) United States $9.789B 27.58
Doximity (DOCS) United States $9.620B 56.63
Charles River Laboratories (CRL) United States $9.516B 18.39
HealthEquity (HQY) United States $8.966B 48.66
Sonic Healthcare (SKHHY) Australia $8.758B 0.00
Bausch + Lomb (BLCO) Canada $6.885B 32.05
Life Times (LTH) United States $5.085B 33.66
Sotera Health (SHC) United States $3.855B 20.62
Organon (OGN) United States $3.757B 3.79
BrightSpring Health Services (BTSG) United States $3.247B 69.07
Surgery Partners (SGRY) United States $2.892B 32.97
PACS (PACS) United States $2.606B 0.00
Concentras Parent (CON) United States $2.581B 0.00
Ardent Health Partners (ARDT) United States $2.375B 0.00
Premier (PINC) United States $2.143B 11.15
Alignment Healthcare (ALHC) United States $2.126B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GeneDx Holdings (WGS) United States $1.952B 0.00
GoodRx Holdings (GDRX) United States $1.616B 42.40
Teladoc Health (TDOC) United States $1.537B 0.00
Pediatrix Medical (MD) United States $1.255B 12.28
CareDx (CDNA) United States $1.183B 0.00
Progyny (PGNY) United States $1.164B 23.57
Establishment Labs Holdings (ESTA) $1.050B 0.00
AMN Healthcare Services Inc (AMN) United States $0.954B 6.46
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Embecta (EMBC) United States $0.778B 5.18
SBC Medicals (SBC) United States $0.677B 0.00
Agilon Health (AGL) United States $0.655B 0.00
InnovAge Holding (INNV) United States $0.647B 0.00
Auna S.A (AUNA) Luxembourg $0.536B 0.00
Sonida Senior Living (SNDA) United States $0.425B 0.00
DocGo (DCGO) United States $0.410B 15.46
Enhabit (EHAB) United States $0.366B 31.61
COMPASS Pathways (CMPS) United Kingdom $0.326B 0.00
LifeMD (LFMD) United States $0.241B 0.00
ModivCare (MODV) United States $0.223B 12.09
Sera Prognostics (SERA) United States $0.209B 0.00
Beauty Health (SKIN) United States $0.200B 0.00
Biodesix (BDSX) United States $0.180B 0.00
Nutex Health (NUTX) United States $0.156B 0.00
Ascend Wellness Holdings (AAWH) United States $0.100B 0.00
So-Young (SY) China $0.092B 22.25
MultiPlan (MPLN) United States $0.084B 0.00
Singular Genomics Systems (OMIC) United States $0.054B 0.00
OncoCyte (OCX) United States $0.043B 0.00
NeueHealth (NEUE) United States $0.041B 1.08
Co-Diagnostics (CODX) United States $0.034B 0.00
Pheton Holdings (PTHL) China $0.030B 0.00
IceCure Medical (ICCM) Israel $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.020B 0.00
Oncology Institute (TOI) United States $0.014B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00